Overview

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Status:
Terminated

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of siltuximab administered in combination with mitoxantrone and prednisone in participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).

Phase:

Phase 2

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Antibodies, Monoclonal
Hormones
Mitoxantrone
Prednisone
Siltuximab